ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p757.xmlResistance to Imatinib: Mechanisms and Management2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p757.pdf2026-04-18Resistance to Imatinib: Mechanisms and Managementhttps://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p731.xmlIf Only It Were Simple2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p731.pdf2026-04-18If Only It Were Simplehttps://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p732.xmlChronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p807.xmlBenefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p807.pdf2026-04-18Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p796.xmlCancer Patient Survival and Erythropoietin2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p796.pdf2026-04-18Cancer Patient Survival and Erythropoietinhttps://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p791.xmlParenteral Iron Therapy: A Single Institution's Experience Over a 5-Year Period2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p791.pdf2026-04-18Parenteral Iron Therapy: A Single Institution's Experience Over a 5-Year Periodhttps://harbor.dev.pubfactory.com/view/journals/jnccn/3/6/article-p772.xmlCancer- and Treatment-Related Anemia Clinical Practice Guidelines in Oncology2026-04-18